PREVENTIVE AGENT OR THERAPEUTIC AGENT FOR RENAL DISORDERS
|Posted date||Jan 29, 2021|
|International application number||2020JP001598|
|International publication number||WO 2020255464|
|Date of international filing||Jan 17, 2020|
|Date of international publication||Dec 24, 2020|
|Title||PREVENTIVE AGENT OR THERAPEUTIC AGENT FOR RENAL DISORDERS|
|Abstract||Provided is a novel preventive agent or therapeutic agent for renal disorders. This preventive agent or therapeutic agent for renal disorders contains a thioredoxin derivative as an active ingredient.|
|Outline of related art and contending technology||
Renal disorders are diseases with high mortality and poor prognosis. For example, in severe acute nephropathy (acute kidney injury: AKI), the mortality rate is greater than 50 %.
Upon transition (AKI to CKD transition) from acute renal injury to chronic renal disease, some of the patients need to undergo dialysis. The number of patients who required dialysis due to the transition from acute renal injury to chronic renal disease has been said to reach approximately 80,000 dialyzed patients in Japan at approximately 1/4 (approximately 80,000 people).
Research has been underway on the mechanism of transitioning from acute renal injury to chronic renal disease. (Non-Patent Document 1) has been reported that stopping of the cell cycle of renal cells without progression from phase G2 to phase m is one of the mechanisms of transitioning from acute renal injury to chronic renal disease.
Furthermore, renal disorders can be classified into various classes, and examples of renal disorders include a transition from acute renal disorder to chronic renal disease, calcineurin inhibitor nephropathy, diabetic kidney disease, renal sclerosis, and renal disorders due to ischemia, oxidative stress, or renal interstitial fibrosis, such as renal disorders associated with renal transplantation.
Under the circumstances described above, attention has attracted attention to the development of prophylactic agents and therapeutic agents for renal disorders. For acute renal disorders associated with cardiac surgery, methods of treating patients with the inhibitor (QPI-1002) of p53 are currently in progress and for which a Phase III trial is currently being conducted.
|Scope of claims||
|IPC(International Patent Classification)||
National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JO JP KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN WS ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL ST SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN TD TG
Contact Information for " PREVENTIVE AGENT OR THERAPEUTIC AGENT FOR RENAL DISORDERS "
- National University Corporation University of Fukui Headquarters for Innovative Society-Academia Cooperation
- URL: https://www.u-fukui.ac.jp/
- Address: 9-1, Bunkyo 3-chome, Fukui-shi, Fukui, Japan , 910-8507
- Fax: 81-776-27-9727